Registration needed. No charge.
It is our pleasure to welcome you to the 2nd ELRIG bi-annual conference on Advances in Cell Based Screening in Drug Discovery to be held on the 10th and 11th of May 2017 at AstraZeneca in Gothenburg. This interactive 2-day event will host leading scientists from academia and industry, coming together to discuss the latest developments in cell based screening in drug discovery.
Cell based assays and screens are utilized in drug discovery to explore disease mechanisms and identify novel molecular therapeutics. Significant efforts have therefore been dedicated to developing cell-based assay platforms capable of providing a more accurate biological context and thus reduce the number of animal tests, improve translation to human physiology/pathophysiology and accelerate the drug discovery process.
Recent developments in assay and detection technologies have improved the sensitivity in drug screening and, together with the application of native cell systems, including primary and stem cell derived cellular models, in early hit and lead identification means that potential novel therapeutic molecules are being applied to human cellular systems earlier than ever.
The program for this ELRIG meeting has been developed to expand scientific horizons in key topic areas such as advanced cell models, applied omics, assays/methods exploring mode of action, phenotypic screening, target deconvolution, and much more. Speakers from leading laboratories, both academic and industrial, will present and discuss the latest updates and advances in cellular systems and drug discovery platforms. Throughout the course of the two day conference, you will get an exclusive opportunity to network and be involved in inspiring and interesting discussions with scientists and researchers from the pharmaceutical, academic and vendor communities.
There will be opportunities for scientists to network and discuss challenges and solutions relating to current and breakthrough assay technologies and provide a platform to assess the true value and impact of new and innovative approaches to cell based drug discovery.